ATE378063T1 - Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden - Google Patents
Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-ligandenInfo
- Publication number
- ATE378063T1 ATE378063T1 AT03767488T AT03767488T ATE378063T1 AT E378063 T1 ATE378063 T1 AT E378063T1 AT 03767488 T AT03767488 T AT 03767488T AT 03767488 T AT03767488 T AT 03767488T AT E378063 T1 ATE378063 T1 AT E378063T1
- Authority
- AT
- Austria
- Prior art keywords
- insulin
- pharmaceutical compositions
- compositions containing
- ligands
- hexamer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201991 | 2002-12-20 | ||
| US43938203P | 2003-01-10 | 2003-01-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE378063T1 true ATE378063T1 (de) | 2007-11-15 |
Family
ID=32683719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03767488T ATE378063T1 (de) | 2002-12-20 | 2003-12-22 | Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1585541B1 (de) |
| JP (1) | JP2006516966A (de) |
| AT (1) | ATE378063T1 (de) |
| AU (1) | AU2003291972A1 (de) |
| DE (1) | DE60317565T2 (de) |
| ES (1) | ES2297227T3 (de) |
| WO (1) | WO2004056347A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037927B2 (en) | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| WO2005080367A1 (en) * | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| BRPI0512988A (pt) | 2004-07-08 | 2008-04-22 | Novo Nordisk As | método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica |
| JP2008505866A (ja) * | 2004-07-09 | 2008-02-28 | ノボ ノルディスク アクティーゼルスカブ | インスリンを含有する薬学的製剤 |
| US20080280814A1 (en) * | 2004-09-17 | 2008-11-13 | Novo Nordisk A/S | Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide |
| DE102005022182A1 (de) * | 2005-05-09 | 2006-11-16 | Combinature Biopharm Ag | Modulatoren der PDZ-Domäne |
| TW200800978A (en) * | 2006-03-23 | 2008-01-01 | Otsuka Pharma Co Ltd | Carbazole compound |
| JP5191155B2 (ja) * | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
| WO2015095265A1 (en) * | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
| JP2017538712A (ja) | 2014-12-11 | 2017-12-28 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 細胞壊死の抑制剤及びそれに関連する方法 |
| ES2935722T3 (es) * | 2017-07-28 | 2023-03-09 | Novartis Ag | Derivados de indol y usos de los mismos |
| KR20210020865A (ko) * | 2018-03-16 | 2021-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 | 퍼옥시솜 증식자-활성화 수용체 알파의 효능제 및 사용 방법 |
| EP4083037A4 (de) * | 2019-12-26 | 2024-01-24 | Yonsei University, University-Industry Foundation(UIF). | Pyrrolidinderivat und pharmazeutische zusammensetzung zur vorbeugung oder behandlung von beta-amyloid- oder tau-protein-assoziierten krankheiten, die diese enthalten |
| CN113929588B (zh) * | 2020-06-29 | 2023-08-15 | 沈阳化工研究院有限公司 | 一种合成4-氨基甲基苯甲酸的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| US5830999A (en) * | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
| EP1396272A1 (de) * | 1997-12-23 | 2004-03-10 | Eli Lilly & Company | Unlöslische Insulin Zusammensetzungen zur Regelung der Blutglukose |
| PL369119A1 (en) * | 2001-09-14 | 2005-04-18 | Novo Nordisk A/S | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer |
-
2003
- 2003-12-22 JP JP2005502527A patent/JP2006516966A/ja not_active Withdrawn
- 2003-12-22 ES ES03767488T patent/ES2297227T3/es not_active Expired - Lifetime
- 2003-12-22 DE DE60317565T patent/DE60317565T2/de not_active Expired - Fee Related
- 2003-12-22 EP EP03767488A patent/EP1585541B1/de not_active Expired - Lifetime
- 2003-12-22 AT AT03767488T patent/ATE378063T1/de not_active IP Right Cessation
- 2003-12-22 AU AU2003291972A patent/AU2003291972A1/en not_active Abandoned
- 2003-12-22 WO PCT/DK2003/000931 patent/WO2004056347A2/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP1585541A2 (de) | 2005-10-19 |
| AU2003291972A8 (en) | 2004-07-14 |
| DE60317565D1 (de) | 2007-12-27 |
| ES2297227T3 (es) | 2008-05-01 |
| JP2006516966A (ja) | 2006-07-13 |
| EP1585541B1 (de) | 2007-11-14 |
| WO2004056347A2 (en) | 2004-07-08 |
| AU2003291972A1 (en) | 2004-07-14 |
| DE60317565T2 (de) | 2008-09-11 |
| WO2004056347A3 (en) | 2004-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE378063T1 (de) | Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden | |
| ATE382057T1 (de) | Stabile formulierung von modifiziertem glp-1 | |
| DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
| IS6658A (is) | Ný efnasambönd | |
| MXPA04002404A (es) | Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r. | |
| BR0210078A (pt) | Composto, uso do mesmo, e, formulação farmacêutica | |
| PT1263724E (pt) | Novos compostos | |
| SE0104140D0 (sv) | Novel Compounds | |
| DE50206657D1 (de) | Pharmazeutische zusammensetzung zur behandlung von multiple sklerose | |
| NO20054555L (no) | Farmasoytiske preparater som omfatter syrestabilisert insulin | |
| DE60334773D1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
| SE0302139D0 (sv) | Novel compounds | |
| EA200401526A1 (ru) | Новые соединения и их применение | |
| CY1109361T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
| ATE302203T1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| SE0101038D0 (sv) | Novel compounds | |
| SE0102716D0 (sv) | Novel compounds | |
| BR0312889A (pt) | Polipeptìdeo t20 peguilado | |
| SE0303280D0 (sv) | Novel compounds | |
| MXPA03008801A (es) | Aril oxima-piperazinas utiles como antagonistas de ccr5. | |
| SE0302755D0 (sv) | Novel compounds | |
| SE0202693D0 (sv) | Compounds | |
| SE0202692D0 (sv) | Compounds | |
| CY1106964T1 (el) | Φαρμακα που περιεχουν ν,ν’-διυποκατεστημενες ενωσεις πιπεραζινης και η χρησιμοποιηση τους | |
| CY1105363T1 (el) | Ν,ν΄-διυποκατεστημενες ενωσεις πιπepαζινης και η χρηση τους σαν αναλγητικα μεσα |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |